Substance P ameliorates tumor necrosis factor-alpha-induced endothelial cell dysfunction by regulating eNOS expression in vitro

Microcirculation. 2018 Apr;25(3):e12443. doi: 10.1111/micc.12443.

Abstract

Objective: The aim of this study was to explore the beneficial effects of SP on NO production and inflammation-induced vascular endothelium cell death.

Methods: To mimic the inflammatory environment, TNF-α was treated with HUVECs, and SP was added prior to TNF-α to determine its protective effect. WST-1 assay was performed to detect cell viability. NO level in conditioned medium was measured by Griess Reagent System. The protein level of cleaved caspase-3, eNOS, and phosphorylated Akt was detected by Western blot analysis.

Results: TNF-α declined endothelial cell viability by downregulating Akt and NO production. TNF-α-induced cell death was reliably restored by NO, confirming the requirement of NO for cell survival. By contrast, pretreatment of SP attenuated TNF-α-induced cellular apoptosis, accompanied by an increase in the phosphorylation of Akt, eNOS expression, and NO production. Blockage of NK-1R, phosphorylated Akt or eNOS by CP-96345, A6730, or L-NAME entirely eliminated the effect of SP.

Conclusions: SP can protect the vascular endothelium against inflammation-induced damage through modulation of the Akt/eNOS/NO signaling pathway.

Keywords: inflammation; nitric oxide; substance P; vascular endothelium.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / pathology*
  • Endothelium, Vascular / physiopathology
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • Inflammation / chemically induced
  • Inflammation / drug therapy
  • Neurotransmitter Agents / therapeutic use
  • Nitric Oxide / biosynthesis
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type III / drug effects
  • Nitric Oxide Synthase Type III / metabolism*
  • Proto-Oncogene Proteins c-akt / metabolism
  • Signal Transduction / drug effects
  • Substance P / pharmacology*
  • Substance P / therapeutic use
  • Tumor Necrosis Factor-alpha / adverse effects

Substances

  • Neurotransmitter Agents
  • TNF protein, human
  • Tumor Necrosis Factor-alpha
  • Nitric Oxide
  • Substance P
  • NOS3 protein, human
  • Nitric Oxide Synthase Type III
  • Proto-Oncogene Proteins c-akt